Molecule News and Research

RSS

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

The Leukemia & Lymphoma Society and FORMA Therapeutics, Inc., today announced they have begun a partnership to discover and develop small molecule compounds against a key lymphoma target, Bcl-6.

15 Mar 2010

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

YM BioSciences Inc., today announced that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 17-21 in Washington, DC. The first poster describes the results of the previously reported collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The poster will describe activity of 111In-NLS-nimotuzumab against breast cancer cells with high and low EGFR expression.

15 Mar 2010

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

Chemotherapy, followed by the surgical removal of the affected tissue is the treatment usually adapted to bone tumors. An implant which can fill the areas of subtraction, while releasing chemotherapeutical agents locally, in a controlled manner, during the treatment period, is the aim of a research led by the Research Centre in Ceramic Material and Composites (CICECO/UA). In these experiences, specialists are using potential "anti-tumor" drugs coated by nanocapsules.

15 Mar 2010

MPP cell population: A new potential target for treating infections and allergies

Millions of people in both the developing and developed world may benefit from new immune-system research findings from the University of Pennsylvania School of Veterinary Medicine.

15 Mar 2010

Sigma-Aldrich and Pfizer sign new agreement

Sigma-Aldrich® today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to life science researchers for target characterization, assay development, screening and in vivo animal model applications.

15 Mar 2010

Nanoparticles provide a targeted version of photothermal therapy for cancer

In a lecture he delivered in 1906, the German physician Paul Ehrlich coined the term Zuberkugel, or "magic bullet," as shorthand for a highly targeted medical treatment.

15 Mar 2010

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die. When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more.

15 Mar 2010

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Johns Hopkins University's newly formed Brain Science Institute's NeuroTranslational Program has entered into a licensing agreement with pharmaceutical company Eisai Inc. to discover and develop small molecule glutamate carboxypeptidase II (GCPII) inhibitors.

15 Mar 2010

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV), reported recent accomplishments, announced fourth quarter and full-year 2009 financial results and provided key upcoming clinical development milestones and financial guidance for 2010.

12 Mar 2010

StockPreacher.com announces investment report featuring Generex Biotechnology

StockPreacher.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

Achillion Pharmaceuticals reports net loss of $6.7M for three months ended December 31, 2009

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2009.

12 Mar 2010

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

12 Mar 2010

BDNF could someday play significant role in prevention of high blood pressure: Study

Researchers at Oregon Health & Science University's School of Dentistry (www.ohsu.edu/sod) have discovered that nitric oxide is a powerful regulator of a molecule that plays a critical role in the development and function of the nervous system. The finding could someday play a significant role in the prevention and treatment of high blood pressure, which affects about one in three adults in the United States.

12 Mar 2010

New molecule effective against lice

French medical researchers from the AP-HP (Henri Mondor Hospital and Avicenne Hospital) and Inserm (Unit 738 "Models and methods for therapeutic evaluation of chronic illnesses" and CIC 202, at Tours) have recently demonstrated the effectiveness of a new molecule in the fight against lice. Faced with the emergence of increasing resistance to conventional treatments by these parasites, this new medication represents a real therapeutic alternative which is effective in 95% of cases.

12 Mar 2010

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

12 Mar 2010

Discovery of novel cellular mechanism may help develop new treatments for cancer

A research team led by the University of Colorado at Boulder has discovered a previously unknown cellular "switch" that may provide researchers with a new means of triggering programmed cell death, findings with implications for treating cancer.

12 Mar 2010

Novel mutation in gene encoding ankyrin-B increases risk of type 2 diabetes

Alterations in our response to the taste or smell of food may be another culprit responsible for Type 2 diabetes, according to scientists at Duke University Medical Center who have identified the specific mechanism in human specimens and in mice.

12 Mar 2010

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that members of its senior leadership and scientific teams will be leading discussions and presenting data from its novel Hedgehog pathway inhibitor program – an emerging area of cancer research – at several upcoming conferences.

11 Mar 2010

Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression

Evotec AG today announced two positive aspects that strengthen its integrated product development in treatment-resistant depression in its strategic alliance with Roche.

11 Mar 2010

Evotec, Active Biotech announce collaboration to identify small molecule modulators of priority biological target

Evotec AG today announced that it has entered into a collaboration with Active Biotech AB to identify small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.

11 Mar 2010

Molecule News and Research

LLS, FORMA Therapeutics collaborate to develop small molecule compounds against Bcl-6

YM BioSciences: Two posters on nimotuzumab accepted for presentation at AACR

Bone implants that support and release chemotherapeutical agents in ciclodextrin nanocapsule

MPP cell population: A new potential target for treating infections and allergies

Sigma-Aldrich and Pfizer sign new agreement

Nanoparticles provide a targeted version of photothermal therapy for cancer

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Brain Science Institute, Eisai sign licensing agreement to develop GCPII inhibitors

Ardea Biosciences' revenues total $8.3M for three months ended December 31, 2009

StockPreacher.com announces investment report featuring Generex Biotechnology

Achillion Pharmaceuticals reports net loss of $6.7M for three months ended December 31, 2009

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

BDNF could someday play significant role in prevention of high blood pressure: Study

New molecule effective against lice

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

Discovery of novel cellular mechanism may help develop new treatments for cancer

Novel mutation in gene encoding ankyrin-B increases risk of type 2 diabetes

Data from novel Hedgehog pathway inhibitor program to be presented at upcoming conferences

Evotec completes first-in-human Phase I study of EVT 103 for treatment-resistant depression

Evotec, Active Biotech announce collaboration to identify small molecule modulators of priority biological target

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News